All Cell & Gene Therapy articles – Page 8
-
NewsTessera's gene editing offers hope for sickle cell patients
Find out how Tessera's latest advancements in gene editing bring promising solutions to treat sickle cell disease.
-
ArticleIn vivo CAR T: Faster, cheaper, and more effective cancer care
Find out how in vivo cell therapies could transform cancer treatment by providing faster, more affordable, and accessible options for more patients.
-
NewsNKTR-255 shows positive results in lymphoma therapy
Nektar Therapeutics' NKTR-255 improves CAR-T therapy outcomes in lymphoma patients. Find out how this development could impact cancer treatment.
-
ArticleWomen in STEM with Veerle d’Haenens
We had the privilege of talking to Veerle d’Haenens, General Manager, Global Therapy Innovations at Terumo Blood and Cell Technologies. Her successful career has been driven by her creativity, expertise and passion, and she advises women who are aspiring to STEM roles to always think big.
-
NewsMechanism that controls reactivation of neural stem cells discovered
New insights into the role of SUMOylation in the brain could lead to new targeted therapies for neurodegenerative conditions.
-
ArticleThe hidden risks of over-reliance on healthy donor material
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant ...
-
NewsNew platform will accelerate single-cell analysis workflow
Sphere Fluidics have developed the Cyto-Mine® Chroma platform, which provides multiplexing and greater assay flexibility, reducing timelines and cost.
-
ArticleCell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
-
ArticleOvercoming operational challenges in CGT manufacturing with AI
In this Q&A, Dalip Sethi, scientific lead for Terumo Blood and Cell Technologies, Cell Therapy Technologies and Innovation portfolio, discusses the integration of AI into CGT manufacturing processes to enhance operational efficiency and accelerate treatment access. He also elucidates the strategies that are being considered to overcome hurdles when implementing ...
-
ArticleAdvancing CAR-T therapy: how CD5 modulation is shaping cancer treatment
Vittoria Biotherapeutics is pioneering a novel form of CAR-T therapy for T-cell lymphoma using CRISPR gene editing. Here, co-founders Nicholas Siciliano and Marco Ruella explain how their approach promises to overcome tumour resistance, while also offering hope for new ways to treat solid cancers.
-
ArticleMacrophage cell therapy: a new hope for chronic liver disease patients
Resolution Therapeutics is pioneering a novel approach to the treatment of chronic liver disease – by engineering the patient’s own macrophages to include regenerative properties. Cliff Brass, Chief Medical Officer at Resolution Therapeutics, explains how the aim is to reduce inflammation, improve liver function, and ultimately eliminate the need for ...
-
NewsHow 3D tissue shapes emerge in animal development
Researchers showed that internal stress, induced by active cell behaviours, shapes the Drosophila wing disc pouch during eversion.
-
NewsTreating HCC with genetically modified NK-cell therapy
Blocking the TGF-β signalling pathway produced effective antitumour activity against hepatocellular carcinoma.
-
ArticleThe evolution of cell therapy to address unmet medical needs
We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.
-
NewsNew ENaC blocker demonstrates an extended duration of action
The novel drug, ETD001, could provide an improved approach for mucus clearance in cystic fibrosis patients.
-
ReportBeyond the lab: cell and gene therapy
Download this report now to access exclusive content on innovative cancer treatments, regenerative medicine, gene therapy, and expert insights from leading professionals in the field.
-
NewsFOXO1 improves survival and function of CAR T cells
Evidence indicating that FOXO1 plays a unique role in promoting T cell longevity could result in more effective CAR T cell therapies.
-
ArticleFinding the right CDMO partner for cell line development
The commercial production of recombinant proteins, such as antibodies and enzymes, relies on generating and maintaining specific cell lines designed to produce these specialised molecules. However, the creation of cell lines is a technically demanding and time-consuming process. For this reason, many businesses seek partnerships with contract development and manufacturing ...
-
NewsNew strategies to overcome CAR T-cell resistance in AML cells
Pharmacological concomitant therapies or further genetic improvement of CAR T-cells can increase their effectiveness against TP53-mutant AML cells.
-
ArticleDriving efficiency across upstream bioprocess workflow
Dr Anis H Khimani from Revvity explores how key developments have enhanced biotherapeutic workflows, and explores how a transposon system can aid stable clone development.